Trilogy Mets

Trilogy Metals fell 5.1% in regular trading to $3.33, driven by profit-taking after a pre-market spike to $3.699 on news of a strategic equity investment from the U.S. Department of War. The stock opened high but reversed sharply, closing at its intraday low and remaining 70.5% below its 52-week high of $11.29. Q2 net loss widened to $6.345 million (YoY -191.5%), with EPS of -$0.04, though operating loss improved to -$2.09 million from -$4.615 million in Q1. Despite a P/B of 4.96x and turnover of 0.57%, the price has fallen below the 20-day MA of $3.608, suggesting lingering near-term weakness.

Trilogy Metals rallied 7.9% intraday to $3.56, primarily driven by the Pentagon's previously announced strategic equity investment agreement (2.842 million shares at $3.1212/share) and the company's update on the deal's execution progress. The stock opened strong at $3.40 and oscillated higher, peaking at $3.565 by 14:13 ET on 219,615 shares of regular-session volume. However, fundamentals remain strained: Q2 net loss widened 191.46% YoY to -$6.345M, EPS down 201.7% YoY to -$0.04, with ROE at -21.38%. Pre-market traded $3.33-$3.39; after-hours eased to $3.33. Despite slumping 68.47% from its 52-week high of $11.29, the stock has reclaimed its MA60 ($3.46).

TMQ.US traded lower throughout the regular session, closing down 5.0% at $3.305, primarily driven by profit-taking after the U.S. Department of War's strategic equity investment deal was finalized, coupled with ongoing earnings losses. The stock initially surged to an intraday high of $3.550 before reversing, with the intraday low of $3.310 reflecting a >70% decline from the 52-week high of $11.29 and a YTD drop of 28%. Q2 net loss widened to $6.345 million (up 191.5% YoY) with EPS of -$0.04 and zero revenue, underscoring fundamental weakness. However, the stock recovered to $3.450 in after-hours trading, suggesting some investors remain positioned for potential follow-through from the Pentagon partnership.

Trilogy Metals dropped sharply during regular trading as the market digested the recent U.S. Department of War strategic equity investment, refocusing on fundamental pressures. The stock traded between 3.58 and 3.69 in pre-market, but opened at 3.52 and slid steadily, hitting an intraday low of 3.425 at 09:38 ET, closing down ~5.1% on volume of 35.5k shares. News-wise, the company executed definitive agreements for a DoD equity investment, but South32 trimmed its stake to 6%, indicating profit-taking by long-term holders. Earnings show Q2 2026 net loss widened to $6.345M (YoY -191.46%), with EPS of -$0.04 and zero revenue, highlighting ongoing operational challenges. Price-wise, at 3.425, the stock is below both its 20-day MA (3.718) and 60-day MA (3.487), YTD down 25.38%, and sits 69.66% below its 52-week high of 11.29, though still 120.26% above the low of 1.555. However, post-market trading saw the price recover to 3.62, suggesting some dip-buying interest.

TMQ.US weakened significantly during regular trading, sliding from an early session high of $4.00 (matching pre-market peak) to close at $3.761, a decline of approximately 5.0%, driven by a Q2 net loss widening 191.5% YoY to $6.345 million with zero revenue, and a lack of fresh catalysts following the update on the U.S. Department of War's strategic equity investment. At $3.761, the stock remains 66.7% below its 52-week high of $11.29, though it trades slightly above the 20-day MA of $3.561, with a YTD decline of 18.1%. However, the company's established permitting timeline for the Arctic Project through September 2028 provides a measure of long-term support.